The
Apffel Memorial Lecture is endowed by the Apffel family and is given
each year by an outstanding Cancer Researcher to honor
Charles
A. Apffel, M.D. (1910-1985)
Born in Alsace,
France, Charles Apffel received his medical degree, with specialization
in pediatrics, from the University of Strasbourg in 1945.He practiced
medicine in France for two years following World War II and then moved
to Tangiers, where he worked among the native nomadic tribes in various
settings.
While in Morocco,
Charles Apffel saw that his life work would be in cancer research, and
that the best opportunities for such work were in the USA. Arriving
in America in 1958, he worked for two years with Freddie Homburger,
M.D. at the Bioresearch Institute in Cambridge. Then he moved to the
Pondville Hospital, a State institution established for the care of
cancer patients and for cancer research.
Dr.
Apffel remained at Pondville for twenty-one years, serving as Chief
of the Ira T. Nathanson Research Laboratories from 1973 until this cancer
hospital closed in 1981. His major areas of activity were tumor immunology,
non-immunological defenses against cancer, and factors associated with
tumor growth and regression. He continued his work at the New England
Deaconess Hospital until his death in 1985.
His
interests and knowledge were encyclopedic, especially concerning host
defenses. But his interests extended far beyond medicine, to history,
archaeology, architecture, literature, wine, and much else. He was a
witty and charming conversationalist, an innovator, and a scientist
always seeking new approaches to important unsolved problems.
In the final
phase of his life, stricken with colon cancer, he underwent several
partial hepatic resections to remove metastatic lesions. Recuperating
from his last operation, he was seen working hard on a grant application
to carry his studies forward. During his last few months, he developed
bone disease. He then insisted that his physicians use him as an experimental
subject for some of the investigational treatments that he had helped
to develop.
Charles Apffel
contributed to the science of cancer, and inspired his colleagues to
continue his work. The Charles Alfred Apffel Memorial Lecture on Frontiers
in Cancer Research honors his memory, and his vision of a comprehensive
cancer biology that will lead to the understanding and control of this
ancient and ubiquitous disorder that lies at the very root of life.
The
following Apffel memorial lectures have been presented:
1985-86 G. Barry
Pierce: Epigenetic Mechanisms of Cancer
1986-87 Michael
Sporn: Transforming Growth Factors: Action in Normal and Malignant Cells
1987-88
Paul A. Marks: Induced Differentiation of Transformed Cells
1988-89
Robert C. Gallo: Retroviruses and Cancer
1989-90
Ronald B. Herberman: Natural Killer Cells and Their Potential
for the Treatment of Cancer
1990-91
Stanley E. Order: Cancer Therapy with Radiolabeled Antibodies
1991-92
Emil Frei, III: Selectivity for Chemotherapy
1992-93
Jeffrey Schlom: Recombinant Cancer Vaccines
1993-94
Joan Massague: TGF-beta Receptors and Antiprolifierative Actions
1994-95
Karen H. Antman: Advances in the Understanding and Treatment
of Breast Cancer
1995-96
Judah Folkman: Endogenous Inhibitors of Angiogenesis
1996-97
Robert A. Weinberg: Control of the Cell Cycle
1997-98
Stephen B. Baylin: Gene Inactivation and Promoter Region Methylation
in Cancer
1998-99
Ira Pastan: Recombinant Toxin Therapy of Cancer
1999-2000
Lance Liotta: Beyond Genomics To Proteomics: Technology for the next
revolution in molecular medicine
2000-2001
Arnold Levine: The Regulation of p53 Mediated Apoptosis
2001-2002
Phillip A. Sharp: Biology of RNA, Splicing and Interference
2002-2003
Michael B. Sporn: New Synthetic Triterpenoids Modulate Signaling by
TGF-beta and Inflammatory Cytokines: Basic Mechanisms and Practical
Considerations for Prevention and Treatment of Disease
2003-2004
James Allison: Manipulation of inhibitory costimulation in Tumor Immunotherapy
2004-2005 Charles Sawyers: Kinase inhibitors in Cancer Treatment.
2005-2006 Gail Sonenshein: Controlling Epithelial to Mesenchymal Transition of Cancer Cells.